Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,184 total articles

BofA Flagged Elevated CTA Unwind Risk Despite Recent Rally

BofA Flagged Elevated CTA Unwind Risk Despite Recent Rally

Bank of America analysts say recent market strength has provided some relief for trend-following funds, but positioning remains stretched and the risk of a commodity trading advisor (CTA) unwind is still elevated. Systematic strategies could sell materially in a down market, with estimates as high as $132 billion across models and up to $95 billion…

Hamborner REIT narrows office exposure, issues 2026 FFO and rent guidance

Hamborner REIT narrows office exposure, issues 2026 FFO and rent guidance

Hamborner REIT AG has revised its portfolio composition to materially reduce office weighting and provided guidance for the 2026 financial year, forecasting funds from operations (FFO) between €38.0 million and €42.0 million and expected rental income of €87.5 million to €89.5 million. The firm attributes a projected decline in rental receipts to p…

Citi Stays Bullish on Equities After Strong Q4 Results and Stable Estimates

Citi Stays Bullish on Equities After Strong Q4 Results and Stable Estimates

Citi told clients that fourth-quarter results and steady consensus estimates underpin its optimistic outlook for 2026. Analyst Scott Chronert reiterated that the firm "maintains a constructive fundamental outlook for 2026," citing positive Q4 2025 earnings trends, accelerating sales across market caps and an above-consensus S&P 500 earnings project…

Verisk Launches $1.5 Billion Accelerated Buyback, Shares Tick Higher

Verisk Launches $1.5 Billion Accelerated Buyback, Shares Tick Higher

Verisk Analytics said it entered into accelerated share repurchase (ASR) agreements totaling $1.5 billion with HSBC Bank USA, N.A. and Wells Fargo Bank, N.A. The stock rose 1.5% on the news. The transactions include an initial delivery of about 7.0 million shares and are expected to settle no later than the company’s third fiscal quarter ending Sep…

UBS Flags European Oil Names Best Placed to Gain from Iran Risk Premium

UBS Flags European Oil Names Best Placed to Gain from Iran Risk Premium

UBS updated its geopolitical framework and identified a group of European oil companies it believes are well positioned to benefit if an Iran-related risk premium pushes crude prices higher. The bank sees upstream-exposed producers and certain oil services and chemicals businesses as likely near-term beneficiaries, while integrated majors with disc…

Finland’s IQM to Go Public on NYSE Through SPAC Merger

Finland’s IQM to Go Public on NYSE Through SPAC Merger

Finnish quantum computing company IQM has agreed to merge with special purpose acquisition company Real Asset Acquisition Corp., a move that would bring the startup to the New York Stock Exchange with an initial equity valuation of $1.8 billion. The transaction, contingent on shareholder and regulatory approvals, is targeted to close around June, w…

RBC: Recent Tariff Moves Leave Long-Term U.S. Equity Outlook Intact

RBC: Recent Tariff Moves Leave Long-Term U.S. Equity Outlook Intact

RBC Capital’s U.S. equity strategy team says recent tariff developments do not change its longer-term constructive view on U.S. equities. Head of U.S. equity strategy research Lori Calvasina told clients that near- to intermediate-term effects range from "having little impact" to being "slightly positive," and that companies have demonstrated the a…

Merck to Carve Out Cancer Unit, Citing Keytruda Patent Cliff

Merck to Carve Out Cancer Unit, Citing Keytruda Patent Cliff

Merck announced a reorganization that splits its human-health operations into two businesses, isolating its cancer franchise anchored by Keytruda from its non-oncology medicines. The move comes as Keytruda faces an impending loss of patent protection after generating nearly half of Merck's revenue in 2025 and more than $30 billion in sales that yea…